000277351 001__ 277351
000277351 005__ 20240229162344.0
000277351 0247_ $$2doi$$a10.3389/fimmu.2023.1212546
000277351 0247_ $$2pmid$$apmid:37409132
000277351 0247_ $$2pmc$$apmc:PMC10319254
000277351 0247_ $$2altmetric$$aaltmetric:150295944
000277351 037__ $$aDKFZ-2023-01357
000277351 041__ $$aEnglish
000277351 082__ $$a610
000277351 1001_ $$0P:(DE-HGF)0$$aGouttefangeas, Cécile$$b0
000277351 245__ $$aThe good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer.
000277351 260__ $$aLausanne$$bFrontiers Media$$c2023
000277351 3367_ $$2DRIVER$$aarticle
000277351 3367_ $$2DataCite$$aOutput Types/Journal article
000277351 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688643473_10973$$xReview Article
000277351 3367_ $$2BibTeX$$aARTICLE
000277351 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277351 3367_ $$00$$2EndNote$$aJournal Article
000277351 520__ $$aT cells are main actors of the immune system with an essential role in protection against pathogens and cancer. The molecular key event involved in this absolutely central task is the interaction of membrane-bound specific T cell receptors with peptide-MHC complexes which initiates T cell priming, activation and recall, and thus controls a range of downstream functions. While textbooks teach us that the repertoire of mature T cells is highly diverse, it is clear that this diversity cannot possibly cover all potential foreign peptides that might be encountered during life. TCR cross-reactivity, i.e. the ability of a single TCR to recognise different peptides, offers the best solution to this biological challenge. Reports have shown that indeed, TCR cross-reactivity is surprisingly high. Hence, the T cell dilemma is the following: be as specific as possible to target foreign danger and spare self, while being able to react to a large spectrum of body-threatening situations. This has major consequences for both autoimmune diseases and cancer, and significant implications for the development of T cell-based therapies. In this review, we will present essential experimental evidence of T cell cross-reactivity, implications for two opposite immune conditions, i.e. autoimmunity vs cancer, and how this can be differently exploited for immunotherapy approaches. Finally, we will discuss the tools available for predicting cross-reactivity and how improvements in this field might boost translational approaches.
000277351 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000277351 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277351 650_7 $$2Other$$aT cell receptor
000277351 650_7 $$2Other$$aautoimmunity
000277351 650_7 $$2Other$$acancer
000277351 650_7 $$2Other$$across-reactivity
000277351 650_7 $$2Other$$aimmunotherapy
000277351 7001_ $$aKlein, Reinhild$$b1
000277351 7001_ $$aMaia, Ana$$b2
000277351 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2023.1212546$$gVol. 14, p. 1212546$$p1212546$$tFrontiers in immunology$$v14$$x1664-3224$$y2023
000277351 909CO $$ooai:inrepo02.dkfz.de:277351$$pVDB
000277351 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277351 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000277351 9141_ $$y2023
000277351 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T10:28:02Z
000277351 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T10:28:02Z
000277351 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-11T10:28:02Z
000277351 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-23
000277351 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-23
000277351 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-23
000277351 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-23
000277351 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2023-10-26
000277351 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000277351 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000277351 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000277351 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T10:28:02Z
000277351 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000277351 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000277351 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2023-10-26
000277351 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK Koordinierungsstelle Tübingen$$x0
000277351 980__ $$ajournal
000277351 980__ $$aVDB
000277351 980__ $$aI:(DE-He78)TU01-20160331
000277351 980__ $$aUNRESTRICTED